{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T01:25:58Z","timestamp":1788830758019,"version":"build-2803163510"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,7]]},"DOI":"10.7759\/cureus.55747","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T02:36:01Z","timestamp":1709865361000},"source":"Crossref","is-referenced-by-count":1,"title":["High-Dose Immunoglobulin Therapy for Multiple Thromboembolism in Persisting Heparin-Induced Thrombocytopenia"],"prefix":"10.7759","author":[{"given":"Yasushi","family":"Kudo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Maezawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Irinoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1411910","article-title":"Clinical practice. Heparin-induced thrombocytopenia","volume":"373","author":"Greinacher A","year":"2015","unstructured":"Greinacher A. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med. 2015, 373:252-61. 10.1056\/NEJMcp1411910","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12216921","article-title":"Autoimmune heparin-induced thrombocytopenia","volume":"12","author":"Warkentin TE","year":"2023","unstructured":"Warkentin TE. Autoimmune heparin-induced thrombocytopenia. J Clin Med. 2023, 12:10.3390\/jcm12216921","journal-title":"J Clin Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V72.3.925.925","article-title":"Heparin-induced thrombocytopenia: laboratory studies","volume":"72","author":"Kelton JG","year":"1988","unstructured":"Kelton JG, Sheridan D, Santos A, et al.. Heparin-induced thrombocytopenia: laboratory studies. Blood. 1988, 72:925-30. 10.1182\/blood.V72.3.925.925","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.11.3232.3232","article-title":"Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4","volume":"83","author":"Kelton JG","year":"1994","unstructured":"Kelton JG, Smith JW, Warkentin TE, Hayward CP, Denomme GA, Horsewood P. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood. 1994, 83:3232-9. 10.1182\/blood.V83.11.3232.3232","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615946","article-title":"A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia","volume":"85","author":"Farner B","year":"2001","unstructured":"Farner B, Eichler P, Kroll H, Greinacher A. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost. 2001, 85:950-7. 10.1055\/s-0037-1615946","journal-title":"Thromb Haemost"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.12993","article-title":"Laboratory diagnosis of heparin-induced thrombocytopenia","volume":"41 Suppl 1","author":"Warkentin TE","year":"2019","unstructured":"Warkentin TE. Laboratory diagnosis of heparin-induced thrombocytopenia. Int J Lab Hematol. 2019, 41 Suppl 1:15-25. 10.1111\/ijlh.12993","journal-title":"Int J Lab Hematol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13813","article-title":"Autoimmune heparin-induced thrombocytopenia","volume":"15","author":"Greinacher A","year":"2017","unstructured":"Greinacher A, Selleng K, Warkentin TE. Autoimmune heparin-induced thrombocytopenia. J Thromb Haemost. 2017, 15:2099-114. 10.1111\/jth.13813","journal-title":"J Thromb Haemost"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-111-11-946","article-title":"Correction of severe heparin-associated thrombocytopenia with intravenous immunoglobulin","volume":"111","author":"Frame JN","year":"1989","unstructured":"Frame JN, Mulvey KP, Phares JC, Anderson MJ. Correction of severe heparin-associated thrombocytopenia with intravenous immunoglobulin. Ann Intern Med. 1989, 111:946-7. 10.7326\/0003-4819-111-11-946","journal-title":"Ann Intern Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2019.1636645","article-title":"High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: a review","volume":"12","author":"Warkentin TE","year":"2019","unstructured":"Warkentin TE. High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: a review. Expert Rev Hematol. 2019, 12:685-98. 10.1080\/17474086.2019.1636645","journal-title":"Expert Rev Hematol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2017.03.050","article-title":"IVIg for treatment of severe refractory heparin-induced thrombocytopenia","volume":"152","author":"Padmanabhan A","year":"2017","unstructured":"Padmanabhan A, Jones CG, Pechauer SM, et al.. IVIg for treatment of severe refractory heparin-induced thrombocytopenia. Chest. 2017, 152:478-85. 10.1016\/j.chest.2017.03.050","journal-title":"Chest"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/0741-5214(86)90383-6","article-title":"Aortic mural thrombus: an occult source of arterial thromboembolism","volume":"4","author":"Machleder HI","year":"1986","unstructured":"Machleder HI, Takiff H, Lois JF, Holburt E. Aortic mural thrombus: an occult source of arterial thromboembolism. J Vasc Surg. 1986, 4:473-8. 10.1016\/0741-5214(86)90383-6","journal-title":"J Vasc Surg"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/1358863X16675229","article-title":"Antithrombotic therapy in aortic diseases: a narrative review","volume":"22","author":"Caron F","year":"2017","unstructured":"Caron F, Anand SS. Antithrombotic therapy in aortic diseases: a narrative review. Vasc Med. 2017, 22:57-65. 10.1177\/1358863X16675229","journal-title":"Vasc Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2017-220592","article-title":"Non-atherosclerotic aortic mural thrombus: a rare source of embolism","volume":"2017","author":"Marin-Acevedo JA","year":"2017","unstructured":"Marin-Acevedo JA, Koop AH, Diaz-Gomez JL, Guru PK. Non-atherosclerotic aortic mural thrombus: a rare source of embolism. BMJ Case Rep. 2017, 2017:10.1136\/bcr-2017-220592","journal-title":"BMJ Case Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/236243-high-dose-immunoglobulin-therapy-for-multiple-thromboembolism-in-persisting-heparin-induced-thrombocytopenia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T02:36:04Z","timestamp":1709865364000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/236243-high-dose-immunoglobulin-therapy-for-multiple-thromboembolism-in-persisting-heparin-induced-thrombocytopenia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,7]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.55747","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,7]]}}}